1Y Close · As of Aug 26, 2026
G2GBIO operates in the Pharmaceuticals sector.
Legal name: G2GBIO, Inc.
In fiscal year 2025, G2GBIO (456160) reported revenue of 423 million KRW, down 45.0% from 769 million KRW a year earlier.
Operating profit was -12.2 billion KRW and net income was -12.1 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 694.3 billion KRW, with a P/B of 11.90.
These figures can be verified in the DART filing (receipt no. 20260318001347).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 423M | -12.2B | -12.1B |
| 2024 | 769M | -10.8B | -83.3B |
| 2023 | 740M | -13.1B | -10.5B |
Recent Filings
Material Business Matters (Clinical Trial Results)
Large Shareholding Report (General)
Semi-Annual Report (2026.06)
Checks
3 of 8 checked items currently applicable.
Market Cap & Price: Market cap is above the delisting threshold.
Audit Opinion: Audit opinion: Unqualified (clean).
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-27 | Material Business Matters (Clinical Trial Results) |
| 2026-08-21 | Large Shareholding Report (General) |
| 2026-08-14 | Semi-Annual Report (2026.06) |
| 2026-08-05 | Officer/Major Shareholder Ownership Report |